NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/11/2026 10:46
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization108.12 mln
Float82.31 mln
Earnings Date08/11/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
15
/ 100
Significantly lagging
Debt / Equity
0.02
Debt-free
ROE
-108
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Cognition Therapeutics is a New York-based drug development company focused on treating brain and eye diseases that worsen with age. Its primary drug, CT1812, is taken by mouth and works by targeting a specific protein complex in the body, and is currently being tested in multiple Phase 2 trials for conditions including Alzheimer's disease, a form of vision loss called geographic atrophy, and Lewy body dementia. The company has been working in this field since its founding in 2007.
